Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**UCB4019** is an investigational pharmaceutical drug developed by UCB. It is administered via subcutaneous injection and is currently being evaluated primarily for its safety and tolerability in healthy volunteers, with potential indications in several autoimmune diseases. The mechanism of action has not been formally disclosed; available sources suggest it may be intended for the treatment of immune-mediated diseases such as myasthenia gravis, pemphigus vulgaris, and neuromyelitis optica, but the exact molecular target and pathway are not yet published. - First-in-human clinical studies are ongoing, with a primary focus on single ascending dose trials to assess safety, pharmacokinetics (PK), and pharmacodynamics (PD)[1][3][5][7]. - It is categorized as a small molecule drug[7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ucb4019.